We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.04 | 0.04% | 97.13 | 97.82 | 96.92 | 97.08 | 1,630,756 | 01:00:00 |
From May 2019 to May 2024
By Denise Roland
Novartis AG said earnings fell in the first quarter of the year, on a slide in sales of the company's blockbuster cancer drug Gleevec and investment in new drug launches.
Basel, Switzerland-based Novartis said net income for the three months ended March 31 was $2 billion, a fraction of the $13 billion reported a year earlier, when a $12.8 billion gain on the sale of businesses to GlaxoSmithKline PLC and Eli Lilly and Co gave earnings a boost.
Revenue slipped 3% to $11.6 billion, from $11.9 billion a year ago, missing analyst expectations of $11.89 billion.
Core net income, which strips out one-time impairments or gains, fell 13% to $2.8 billion. That beat the $2.68 billion expected by analysts.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
April 21, 2016 01:48 ET (05:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
